Literature DB >> 27364697

Interference of α-Synuclein Uptake by Monomeric β-Amyloid1-40 and Potential Core Acting Site of the Interference.

Daniel K Y Chan1,2,3, Nady Braidy4,5,6, Ying Hua Xu4,5,6, Tim Chataway7, Feng Guo7, Gilles J Guillemin8, Charlie Teo4,9, Wei Ping Gai10.   

Abstract

Increasing evidence suggests an important role of alpha-synuclein (α-Syn) in the pathogenesis of Parkinson's disease (PD). The inter-neuronal spread of α-Syn via exocytosis and endocytosis has been proposed as an explanation for the neuropathological findings of PD in sub-clinical and clinical phases. Therefore, interfering the uptake of α-Syn by neurons may be an important step in slowing or modifying the propagation of the disease. The purposes of our study were to investigate if the uptake of α-Syn fibrils can be specifically interfered with monomeric β-Amyloid1-40 (Aβ40) and to characterise the core acting site of interference. Using a radioisotope-labelled uptake assay, we found an 80 % uptake reduction of α-Syn fibrils in neurons interfered with monomeric Aβ40, but not β-Amyloid1-42 (Aβ42) as compared to controls. This finding was further confirmed by enzyme-linked immunosorbent assay (ELISA) with α-Syn uptake reduced from about 80 % (Aβ42) to about 20 % (Aβ40) relative to controls. To define the region of Aβ40 peptide capable of the interference, we explored shorter peptides with less amino acid residues from both the C-terminus and N-terminus. We found that the interference effect was preserved if amino acid residue was trimmed to position 11 (from N-terminus) and 36 (from C-terminus), but dropped off significantly if residues were trimmed beyond these positions. We therefore deduced that the "core acting site" lies between amino acid residue positions 12-36. These findings suggest α-Syn uptake can be interfered with monomeric Aβ40 and that the core acting site of interference might lie between amino acid residue positions 12-36.

Entities:  

Keywords:  Interference; α-synuclein; α-synuclein uptake; β-amyloid1–40; β-amyloid1–42

Mesh:

Substances:

Year:  2016        PMID: 27364697     DOI: 10.1007/s12640-016-9644-2

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  23 in total

1.  Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro.

Authors:  Nady Braidy; Wei-Ping Gai; Ying Hua Xu; Perminder Sachdev; Gilles J Guillemin; Xing-Mai Jiang; J William O Ballard; Martin P Horan; Zhi Ming Fang; Beng H Chong; Daniel Kam Yin Chan
Journal:  Neurotox Res       Date:  2013-09-12       Impact factor: 3.911

2.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

3.  Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo.

Authors:  Therese Fagerqvist; Thomas Näsström; Elisabet Ihse; Veronica Lindström; Charlotte Sahlin; Stina M Fangmark Tucker; Alex Kasaryan; Mikael Karlsson; Fredrik Nikolajeff; Heinrich Schell; Tiago F Outeiro; Philipp J Kahle; Lars Lannfelt; Martin Ingelsson; Joakim Bergström
Journal:  Amyloid       Date:  2013-09-20       Impact factor: 7.141

4.  A new method for purification of recombinant human alpha-synuclein in Escherichia coli.

Authors:  Chunjuan Huang; Guoping Ren; Hui Zhou; Chih-chen Wang
Journal:  Protein Expr Purif       Date:  2005-03-30       Impact factor: 1.650

5.  Characterization of the kynurenine pathway in human neurons.

Authors:  Gilles J Guillemin; Karen M Cullen; Chai K Lim; George A Smythe; Brett Garner; Vimal Kapoor; Osamu Takikawa; Bruce J Brew
Journal:  J Neurosci       Date:  2007-11-21       Impact factor: 6.167

6.  Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines.

Authors:  R J Perrin; J E Payton; D H Barnett; C L Wraight; W S Woods; L Ye; J M George
Journal:  Neurosci Lett       Date:  2003-10-02       Impact factor: 3.046

7.  A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).

Authors:  Ronit Shaltiel-Karyo; Moran Frenkel-Pinter; Edward Rockenstein; Christina Patrick; Michal Levy-Sakin; Abigail Schiller; Nirit Egoz-Matia; Eliezer Masliah; Daniel Segal; Ehud Gazit
Journal:  J Biol Chem       Date:  2013-05-01       Impact factor: 5.157

8.  Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

Authors:  Pravat K Mandal; Jay W Pettegrew; Eliezer Masliah; Ronald L Hamilton; Ratna Mandal
Journal:  Neurochem Res       Date:  2006-09-01       Impact factor: 4.414

9.  Oligomer formation of tau protein hyperphosphorylated in cells.

Authors:  Katharina Tepper; Jacek Biernat; Satish Kumar; Susanne Wegmann; Thomas Timm; Sabrina Hübschmann; Lars Redecke; Eva-Maria Mandelkow; Daniel J Müller; Eckhard Mandelkow
Journal:  J Biol Chem       Date:  2014-10-22       Impact factor: 5.157

10.  Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Authors:  Igor F Tsigelny; Leslie Crews; Paula Desplats; Gideon M Shaked; Yuriy Sharikov; Hideya Mizuno; Brian Spencer; Edward Rockenstein; Margarita Trejo; Oleksandr Platoshyn; Jason X-J Yuan; Eliezer Masliah
Journal:  PLoS One       Date:  2008-09-04       Impact factor: 3.240

View more
  5 in total

1.  Plasma biomarkers inclusive of α-synuclein/amyloid-beta40 ratio strongly correlate with Mini-Mental State Examination score in Parkinson's disease and predict cognitive impairment.

Authors:  Daniel Kam Yin Chan; Jack Chen; Ren Fen Chen; Jayesh Parikh; Ying Hua Xu; Peter A Silburn; George D Mellick
Journal:  J Neurol       Date:  2022-07-25       Impact factor: 6.682

Review 2.  Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.

Authors:  Md Sahab Uddin; Anna Stachowiak; Abdullah Al Mamun; Nikolay T Tzvetkov; Shinya Takeda; Atanas G Atanasov; Leandro B Bergantin; Mohamed M Abdel-Daim; Adrian M Stankiewicz
Journal:  Front Aging Neurosci       Date:  2018-01-30       Impact factor: 5.750

Review 3.  Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease.

Authors:  Daniel Kam Yin Chan; Ying Hua Xu; Luke Kar Man Chan; Nady Braidy; George D Mellick
Journal:  Transl Neurodegener       Date:  2017-12-20       Impact factor: 8.014

4.  Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.

Authors:  Antonio Dominguez-Meijide; Eftychia Vasili; Annekatrin König; Maria-Sol Cima-Omori; Alain Ibáñez de Opakua; Andrei Leonov; Sergey Ryazanov; Markus Zweckstetter; Christian Griesinger; Tiago F Outeiro
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

5.  Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease.

Authors:  Nai-Ching Chen; Hsiu-Ling Chen; Shau-Hsuan Li; Yen-Hsiang Chang; Meng-Hsiang Chen; Nai-Wen Tsai; Chiun-Chieh Yu; Shieh-Yueh Yang; Cheng-Hsien Lu; Wei-Che Lin
Journal:  Front Aging Neurosci       Date:  2020-04-28       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.